<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97517">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01996657</url>
  </required_header>
  <id_info>
    <org_study_id>2013-P-002</org_study_id>
    <nct_id>NCT01996657</nct_id>
  </id_info>
  <brief_title>D-dimer and Oral Anticoagulation Therapy in Patients With Mechanical Valve Replacement</brief_title>
  <acronym>DDandOAT</acronym>
  <official_title>D-dimer Levels Predict Subsequent Prognosis in Patients Post-mechanical Valves Replacement During Oral Anticoagulation Therapy ：a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Asia Heart Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TO evaluate Whether the D-dimer levels could predict the Subsequent Thromboembolic and
      Cardiovascular Events in Patients post-mechanical valves replacement during oral
      anticoagulation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with mechanical valves replacements need anticoagulation in lifetime,warfarin is
      the most widely used oral anticoagulants，and the extent of anticoagulation should suitable
      and be monitored，Prothrombin time（PT） derivative International Normalized Ratio(INR)is the
      best monitor parameter，and have a well recognized therapy range：2.0-3.0。 Is it enough only
      using INR to monitor the anticoagulants therapy？Because some clinicians found some patient
      still have poor prognosis even though their INR were suitable。 This study is to evaluate
      Whether the D-dimer could be a necessary supplement for INR，to monitor oral anticoagulation
      therapy in patients post-mechanical valves replacement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Thromboembolic Events</measure>
    <time_frame>Up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Thromboembolic Events include venous thromboembolism ,stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vascular Events</measure>
    <time_frame>Up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vascular Events include Cerebral hemorrhage,myocardial infarction ，Cardiac death，Unexplained death.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>Oral Anticoagulants--warfarin</arm_group_label>
    <description>After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin，to keep International normalized ratio in 2.0 to 3.0。 Warfarin  dosage form 3mg/pill，once per day，during a lifetime。</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      BLOOD
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffered mechanical valves replacement because of valves dysfunction; and oral
        anticoagulation therapy with warfarin
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age&gt;18years,male or female without pregnancy;

          2. Suffered the mechanical valves replacement in Wuhan Asia Heart Hospital;

          3. The operation type was aortic valve replacement and/or Mitral valve replacement .

        Exclusion Criteria:

          1. deep venous thromboembolism

          2. Pulmonary embolism

          3. Aortic dissection

          4. stroke

          5. Cerebral hemorrhage

          6. Myocardial infarction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhang zhenlu, PH.D</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan Asia Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhou xin, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Wuhan Asia Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>liu ze jin, PH.D</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan Asia Heart Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhang li tao, MD.P</last_name>
      <phone>+86 02765796739</phone>
      <email>zhangleetau@163.com</email>
    </contact>
    <investigator>
      <last_name>zhang li tao, MD.P</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mechanical valves replacement</keyword>
  <keyword>INR</keyword>
  <keyword>D-dimer</keyword>
  <keyword>thromboembolic events</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
